References
- Schlag P., Manasterski M., Gerneth T., et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol. Immunother. 1992; 35: 325–330
- Vermorken J.B., Claessen A.M., van Tinteren H., et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345–350
- Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
- Morse M.A., Lyerly H.K. Immunotherapy of cancer using dendritic cells. Cytokines Cell. Mol. Ther. 1998; 4: 35–44
- Nair S.K., Boczkowski D., Morse M.A., et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotech. 1998; 16: 364–369
- Boczkowski D., Nair S., Snyder D., et al. Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo. J. Exp. Med. 1996; 184: 465–472
- Thompson J.A., Grunert F., Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical prospectives. J. Clin. Lab. Anal. 1991; 5: 344–366
- Nair S.K., Hull S., Coleman D., et al. Induction of carcinoembryonic antigen (CEA)-specific CTL responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer 1999; 82: 121–124
- Morse M.A., Deng Y., Coleman D., et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 1999; 5: 1331–1338
- Murphy G.P., Tjoa B.A., Simmons S.J., et al. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 2000; 43: 59–62
- Hsu F.J., Benike C., Fagnoni F., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 1996; 2: 52–58
- Lim S.H., Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 1999; 83: 215–222
- Kugler A., Stuhler G., Walden P., et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 2000; 6: 332–336
- Rieser C., Ramoner R., Holtl L., et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int. 2000; 63: 151–159
- Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998; 4: 328–332
- Boczkowski D., Nair S.K., Nam J.H., et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000; 60: 1028–1034
- Bryhni B., Aanderud S., Sundsford J., et al. Thyroid antibodies in northern Norway: prevalence persistence and relevance. J. Intern. Med. 1996; 239: 517–523
- Fyssas I., Syrigos K.N., Konstantoulakis M.M., et al. Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Acta Oncol. 1997; 36: 65–68
- Hughes K.S., Simon R., Songhorabodi S., et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100: 278–284
- Disis M.L., Schiffman K., Gooley T.A., et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 2000; 6: 1347–1350
- Viewig J.W., Coleman D., Maurice M., et al. Immunotherapy of prostate cancer using dendritic cells transfected with PSA RNA: results of a phase I trial. Proc. Am. Soc. Clin. Oncol. 2001; 20: 251a, (abstract #1003)
- Morse M.A., Lyerly H.K., Gilboa E., et al. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 1998; 58: 2965–2969